Ken Griffin Tempest Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	SELL	$0.77 - $9.59 $4,697 - $58,499	-6,100 Reduced 17.68%	28,400 $272,000
Q4 2024 Feb 14, 2025	BUY	$0.7 - $1.45 $4,900 - $10,150	7,000 Added 25.45%	34,500 $28,000
Q3 2024 Nov 14, 2024	SELL	$0.96 - $2.23 $2,016 - $4,683	-2,100 Reduced 7.09%	27,500 $38,000
Q2 2024 Aug 14, 2024	BUY	$2.01 - $5.44 $32,360 - $87,584	16,100 Added 119.26%	29,600 $64,000
Q1 2024 May 15, 2024	BUY	$3.16 - $4.66 $40,764 - $60,114	12,900 Added 2150.0%	13,500 $52,000
Q4 2023 Feb 14, 2024	BUY	$0.23 - $9.77 $138 - $5,862	600 New	600 $2,000

820K

400

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $106M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.